DOCSLIB.ORG

Drug Metabolism Determines Resistance of Colorectal Cancer to Resorcinol-Based HSP90 Inhibitors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Metabolism Determines Resistance of Colorectal Cancer to Resorcinol-Based HSP90 Inhibitors Drug Metabolism Determines Resistance of Colorectal Cancer to Resorcinol-Based HSP90 Inhibitors Dissertation for the award of the degree “Doctor rerum naturalium” (Dr. rer. nat.) in the “Biology of Cells” Program at the Georg August University Göttingen, Faculty of Biology submitted by Hannes Landmann born in Hannover, Germany Göttingen, August 2014 Thesis Committee Prof. Dr. Matthias Dobbelstein Institute for Molecular Oncology, Faculty of Medicine Prof. Dr. Heidi Hahn Tumor Genetics, Department of Human Genetics, Faculty of Medicine Prof. Dr. Dieter Kube Department for Hematology and Oncology, Faculty of Medicine Members of the Examination Board Referee: Prof. Dr. Matthias Dobbelstein, Institute for Molecular Oncology 2nd Referee: Prof. Dr. Heidi Hahn, Tumor Genetics, Department of Human Genetics Further members of the Examination Board Prof. Dr. Dieter Kube Department for Hematology and Oncology, Faculty of Medicine PD Dr. Halyna Shcherbata Research Group Gene Expression and Signaling, Max Planck Institute for Biophysical Chemistry Prof. Dr. Ralph Kehlenbach Department of Molecular Biology, Faculty of Biochemistry PD Dr. Wilfried Kramer Department for Molecular Genetics, Institute for Microbiology and Genetics Date of oral examination: 19th of September 2014 AFFIDAVIT Herewith I declare that I prepared the PhD thesis “Drug Metabolism Determines Resistance of Colorectal Cancer to Resorcinol-Based HSP90 Inhibitors” on my own with no other aids and sources than quoted. _____________________ Hannes Landmann, Göttingen in August 2014 The findings in this work were accepted for publication in the open access journal Cell Death and Disease: Landmann, H., Proia, D.A., He, S., Ogawa, L.S., Kramer, F., Beißbarth, T., Grade, M., Gaedcke, J., Ghadimi, M., Moll, U. & Dobbelstein, M. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. Cell Death and Disease (accepted for publication in July 2014). Table of Contents Table of Contents ............................................................................................................... i List of Figures................................................................................................................... iv List of Tables ..................................................................................................................... v Abbreviations ................................................................................................................... vi Abstract.............................................................................................................................. 1 1. Introduction ........................................................................................................... 3 1.1 Global Perspective on Cancer Treatment .......................................................... 3 1.2 Colorectal Cancer .............................................................................................. 3 1.3 The Chaperone Protein HSP90 ......................................................................... 4 1.4 HSP90 Clients Involved in Cancer.................................................................... 6 1.5 Inhibition of HSP90 as a Cancer Therapy Approach ........................................ 7 1.5.1 The First Generation of HSP90 Inhibitors: Derivatives of Geldanamycin . 8 1.5.2 The Second Generation of HSP90 Inhibitors: Small Synthetic Molecules . 9 1.5.3 Rationale for the Clinical Use of HSP90 Inhibitors .................................. 11 1.5.4 Potential Risks Linked to the Clinical Use of HSP90 Inhibitors .............. 11 1.5.5 Varying Pharmacology of Different HSP90 Inhibitors ............................. 12 1.6 Enzymes of the Drug Metabolism ................................................................... 14 1.6.1 Enzymes from the Phase I of the Drug Metabolism ................................. 14 1.6.2 Enzymes from the Phase II of the Drug Metabolism ................................ 15 1.6.3 The UDP-Glucuronosyltransferases and Their Role in Drug Metabolism16 1.7 Scope of the Thesis ......................................................................................... 19 2. Materials and Methods ........................................................................................ 20 2.1 Materials .......................................................................................................... 20 2.1.1 Technical Devices ..................................................................................... 20 2.1.2 Consumables ............................................................................................. 21 2.1.3 Chemicals and Reagents............................................................................ 22 2.1.4 Eukaryotic Cell Culture ............................................................................. 26 2.1.5 Bacteria...................................................................................................... 27 2.1.6 Bacteria Culture Medium .......................................................................... 27 2.1.7 Oligonucleotides and plasmids.................................................................. 27 2.1.8 Software .................................................................................................... 28 i 2.2 Methods ........................................................................................................... 29 2.2.1 Cell Biology .............................................................................................. 29 2.2.2 Molecular Biology..................................................................................... 33 2.2.3 Protein biochemistry ................................................................................. 38 2.2.4 Statistical Analysis .................................................................................... 40 3. Results ................................................................................................................. 42 3.1 Expression of UGT1A Correlates with Resistance to Ganetespib Treatment 42 3.2 UGT1A Knockdown Sensitizes Resistant CRC Cell Lines to Ganetespib ..... 44 3.3 Overexpression of UGT1A10 Renders Sensitive Cells Resistant to Ganetespib Treatment ....................................................................................... 46 3.4 Verification of Ganetespib Glucuronidation by LC-MS/MS .......................... 49 3.5 UGT1A Expression Levels do not Correlate to Susceptibility to the First Generation Inhibitor 17-AAG ........................................................................... 52 3.6 Susceptibility of Ganetespib-Resistant and -Sensitive Cell Lines to Second Generation HSP90 Inhibitors ............................................................................ 53 4. Discussion ........................................................................................................... 55 4.1 UGT1A Renders CRC Cells Resistant to Ganetespib ..................................... 55 4.2 UGT1A and the Resistance to Other Anti-Cancer Drugs ............................... 56 4.3 Implications for the Different Classes of HSP90 Inhibitors ........................... 57 4.4 Role of UGT1A Glucuronidation in Other Cancer Types .............................. 58 4.5 Other Factors that Might Influence the Efficacy of Glucuronidation by UGT1A ............................................................................................................. 59 4.5.1 Transcriptional Regulation ........................................................................ 59 4.5.2 Factors Regulating the Activity of UGT1A .............................................. 61 4.5.3 Potential Influence of Co-Substrate Supply .............................................. 62 4.5.4 Potential Influence of Metabolite Transport ............................................. 62 4.6 UGT1A Isoforms in Ganetespib Resistance ................................................... 63 4.7 Strategies to Circumvent Ganetespib Resistance by Glucuronidation ............ 64 4.8 Implications for the Clinical Use of Resorcinolic HSP90 Inhibitors .............. 65 4.8.1 Mouse Models for in vivo Studies of Resorcinolic Hsp90 Inhibitors ....... 66 4.8.2 Clinical Studies ......................................................................................... 67 4.9 UGT1A as a Drug-Related Biomarker for Ganetespib Treatment .................. 68 4.9.1 Clinical Assessment of UGT1A mRNA Levels ........................................ 69 4.9.2 Standardization of the mRNA Evaluation Process ................................... 70 ii 4.10 Concluding Remarks ....................................................................................... 71 5. Literature ............................................................................................................. 72 6. Appendix ............................................................................................................. 82 6.1 Gene List from the Statistical Analysis ........................................................... 82 Acknowledgement ........................................................................................................... 85 iii List of Figures Figure 1.1: The HSP90 chaperoning cycle ................................................................................ 6 Figure 1.2: Chemical structures of geldanamycin derivatives. .................................................
Load more

Recommended publications
  • Familial Nephropathy and Multiple Exostoses with Exostosin-1 (EXT1) Gene Mutation
    PATHOPHYSIOLOGY of the RENAL BIOPSY www.jasn.org Familial Nephropathy and Multiple Exostoses With Exostosin-1 (EXT1) Gene Mutation Ian S. D. Roberts* and Jonathan M. Gleadle† *Department of Cellular Pathology, John Radcliffe Hospital, Headley Way, Headington, Oxford, United Kingdom; and †Renal Unit, Level 6, Flinders Medical Centre, Bedford Park, South Australia, Australia ABSTRACT Glomerular deposition of fibrillar collagen is a characteristic finding of genetically mained in remission with trace protein- distinct conditions, including nail-patella syndrome and collagen type III glomeru- uria until cyclosporine was stopped 3.5 lopathy. A case of familial nephropathy in which steroid-sensitive nephrotic syn- yr later. Six months after this, she suf- drome and glomerular deposits of fibrillar collagen are associated with multiple fered another relapse of nephrotic exostoses due to mutation of the EXT1 gene is described. This gene encodes a syndrome that responded to 60 mg pred- glycosyltransferase required for synthesis of heparan sulfate glycosaminoglycans. nisolone and reintroduction of cyclo- There is deficiency of heparan sulfate and perlecan, together with accumulation of sporine. After a further relapse 18 mo collagens, in the matrix of EXT1-associated osteochondromas. Similar glomerular later and because of the development of basement membrane abnormalities could offer an explanation for both the renal adverse corticosteroid effects, she was ultrastructural changes and steroid-sensitive nephrotic syndrome. treated with a 2-mo course of cyclophos- phamide (2.5 mg/kg, orally). Ten years J Am Soc Nephrol 19: 450–453, 2008. doi: 10.1681/ASN.2007080842 after her initial presentation, she remains in full remission and off steroids. Renal function has remained normal through- A 37-yr-old woman presented with the history of renal disease and hearing im- out with a current serum creatinine of nephrotic syndrome.
    [Show full text]
  • CRISPR Screening of Porcine Sgrna Library Identifies Host Factors
    ARTICLE https://doi.org/10.1038/s41467-020-18936-1 OPEN CRISPR screening of porcine sgRNA library identifies host factors associated with Japanese encephalitis virus replication Changzhi Zhao1,5, Hailong Liu1,5, Tianhe Xiao1,5, Zichang Wang1, Xiongwei Nie1, Xinyun Li1,2, Ping Qian2,3, Liuxing Qin3, Xiaosong Han1, Jinfu Zhang1, Jinxue Ruan1, Mengjin Zhu1,2, Yi-Liang Miao 1,2, Bo Zuo1,2, ✉ ✉ Kui Yang4, Shengsong Xie 1,2 & Shuhong Zhao 1,2 1234567890():,; Japanese encephalitis virus (JEV) is a mosquito-borne zoonotic flavivirus that causes ence- phalitis and reproductive disorders in mammalian species. However, the host factors critical for its entry, replication, and assembly are poorly understood. Here, we design a porcine genome-scale CRISPR/Cas9 knockout (PigGeCKO) library containing 85,674 single guide RNAs targeting 17,743 protein-coding genes, 11,053 long ncRNAs, and 551 microRNAs. Subsequently, we use the PigGeCKO library to identify key host factors facilitating JEV infection in porcine cells. Several previously unreported genes required for JEV infection are highly enriched post-JEV selection. We conduct follow-up studies to verify the dependency of JEV on these genes, and identify functional contributions for six of the many candidate JEV- related host genes, including EMC3 and CALR. Additionally, we identify that four genes associated with heparan sulfate proteoglycans (HSPGs) metabolism, specifically those responsible for HSPGs sulfurylation, facilitate JEV entry into porcine cells. Thus, beyond our development of the largest CRISPR-based functional genomic screening platform for pig research to date, this study identifies multiple potentially vulnerable targets for the devel- opment of medical and breeding technologies to treat and prevent diseases caused by JEV.
    [Show full text]
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • Selectin Ligand Sialyl-Lewis X Antigen Drives Metastasis of Hormone-Dependent Breast Cancers
    Published OnlineFirst October 24, 2011; DOI: 10.1158/0008-5472.CAN-11-1139 Cancer Tumor and Stem Cell Biology Research Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers Sylvain Julien1, Aleksandar Ivetic2, Anita Grigoriadis3, Ding QiZe1, Brian Burford1, Daisy Sproviero1, Gianfranco Picco1, Cheryl Gillett4, Suzanne L. Papp5, Lana Schaffer5, Andrew Tutt3, Joyce Taylor-Papadimitriou1, Sarah E. Pinder4, and Joy M. Burchell1 Abstract The glycome acts as an essential interface between cells and the surrounding microenvironment. However, changes in glycosylation occur in nearly all breast cancers, which can alter this interaction. Here, we report that profiles of glycosylation vary between ER-positive and ER-negative breast cancers. We found that genes involved in the synthesis of sialyl-Lewis x (sLex; FUT3, FUT4, and ST3GAL6) are significantly increased in estrogen receptor alpha-negative (ER-negative) tumors compared with ER-positive ones. SLex expression had no influence on the survival of patients whether they had ER-negative or ER-positive tumors. However, high expression of sLex in ER- positive tumors was correlated with metastasis to the bone where sLex receptor E-selectin is constitutively expressed. The ER-positive ZR-75-1 and the ER-negative BT20 cell lines both express sLex but only ZR-75-1 cells could adhere to activated endothelial cells under dynamic flow conditions in a sLex and E-selectin–dependent manner. Moreover, L/P-selectins bound strongly to ER-negative MDA-MB-231 and BT-20 cell lines in a heparan sulfate (HS)–dependent manner that was independent of sLex expression. Expression of glycosylation genes involved in heparan biosynthesis (EXT1 and HS3ST1) was increased in ER-negative tumors.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Molecular Mechanisms Regulating Copper Balance in Human Cells
    MOLECULAR MECHANISMS REGULATING COPPER BALANCE IN HUMAN CELLS by Nesrin M. Hasan A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland August 2014 ©2014 Nesrin M. Hasan All Rights Reserved Intended to be blank ii ABSTRACT Precise copper balance is essential for normal growth, differentiation, and function of human cells. Loss of copper homeostasis is associated with heart hypertrophy, liver failure, neuronal de-myelination and other pathologies. The copper-transporting ATPases ATP7A and ATP7B maintain cellular copper homeostasis. In response to copper elevation, they traffic from the trans-Golgi network (TGN) to vesicles where they sequester excess copper for further export. The mechanisms regulating activity and trafficking of ATP7A/7B are not well understood. Our studies focused on determining the role of kinase-mediated phosphorylation in copper induced trafficking of ATP7B, and identifying and characterizing novel regulators of ATP7A. We have shown that Ser- 340/341 region of ATP7B plays an important role in interactions between the N-terminus and the nucleotide-binding domain and that mutations in these residues result in vesicular localization of the protein independent of the intracellular copper levels. We have determined that structural changes that alter the inter-domain interactions initiate exit of ATP7B from the TGN and that the role of copper-induced kinase-mediated hyperphosphorylation might be to maintain an open interface between the domains of ATP7B. In a separate study, seven proteins were identified, which upon knockdown result in increased intracellular copper levels. We performed an initial characterization of the knock-downs and obtained intriguing results indicating that these proteins regulate ATP7A protein levels, post-translational modifications, and copper-dependent trafficking.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan
    1226 Vol. 11, 1226–1236, February 1, 2005 Clinical Cancer Research UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan Leslie E. Carlini,1 Neal J. Meropol,1 John Bever,2 irinotecan. Specifically, patients with genotypes conferring Michael L. Andria,2 Todd Hill,2 Philip Gold,3 low UGT1A7 activity and/or the UGT1A9 (dT)9/9 genotype may be particularly likely to exhibit greater antitumor Andre Rogatko,1 Hao Wang,1 and response with little toxicity. Rebecca L. Blanchard1 1 2 Fox Chase Cancer Center, Philadelphia, Pennsylvania; Roche INTRODUCTION Laboratories, Inc., Nutley, New Jersey; and 3Swedish Cancer Institute, Seattle, Washington Colorectal cancer (CRC) is the third most common cancer in both men and women and the third most prevalent cause of cancer-related death (1). A common approach to the systemic ABSTRACT management of metastatic colorectal cancer is a combination Purpose: Capecitabine and irinotecan are commonly of fluoropyrimidine (e.g., 5-fluorouracil or capecitabine) used in the treatment of metastatic colorectal cancer (CRC). and irinotecan (reviewed in ref. 2). Fluoropyrimidines act We hypothesized that germline polymorphisms within genes primarily through the inhibition of thymidylate synthase (TS), related to drug target (thymidylate synthase) or metabolizing resulting in impaired DNA synthesis and cell death. Irinotecan is enzymes (UDP-glucuronosyltransferase, UGT) would impact a camptothecin compound that inhibits DNA topoisomerase I, response and toxicity to the combination of capecitabine plus resulting in an accumulation of DNA damage and cell death. irinotecan (CPT-11). Irinotecan is a prodrug that undergoes conversion by liver Experimental Design: Sixty-seven patients with measur- carboxylesterases to form the active compound SN-38, 7-ethyl- able CRC were treated with irinotecan i.v.
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]